Peptide Briefs

  • What the Research Actually Shows About “Libido Peptides”

    What the Research Actually Shows About “Libido Peptides”

    Peptides and Sexual Function: Research, Claims and Gaps

    Original Posted on Substack | Nov 7, 2026

    Search for “peptides for libido” and you will find a crowded market of claims. Some come from clinical trials. Many come from vendor pages, forums and influencers, and they blur the line between an approved prescription drug, a small early study and an animal result. This piece separates them. It covers four compounds that come up most often: bremelanotide (PT-141), melanotan II, kisspeptin and oxytocin. It does not recommend using any of them, and it gives no dosing.

    Subscribe

    The short version

    • One of these has gone through large, controlled trials for a sexual-function indication and is approved: bremelanotide, for a specific group of women.
    • Melanotan II has a small, old human study and a record of safety warnings. It is not approved for any use.
    • Kisspeptin has produced interesting brain-imaging findings in a small group of healthy men. It has no clinical trial for sexual dysfunction behind it.
    • Oxytocin has a large literature on social behavior and a thin, mixed one on sexual function.
    • Active research is mostly new uses of bremelanotide, not new compounds.
    • A vendor page that blends these four into “peptides for sex” is describing four very different evidence bases as one.

    Bremelanotide (PT-141): the approved one, with narrow limits

    What it is: A melanocortin receptor agonist. The FDA approved it as Vyleesi on June 21, 2019, for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), a condition defined by low desire that causes distress.

    Evidence: The approval rests on two identical 24-week, randomized, double-blind, placebo-controlled phase 3 trials in women aged 19 to 56 in the US and Canada, with an optional 52-week open-label extension. The FDA’s trial summary reports that desire scores improved by about 0.5 to 0.6 points on the scale used, compared with about 0.2 for placebo, and that distress scores fell by about 0.7 points, compared with about 0.4 for placebo. These are modest average changes, and they are what a regulator judged to be enough for approval in that population.

    What the trials also found: Nausea was reported by 40.0% of women on the drug versus 1.3% on placebo, flushing by 20.3% versus 0.3%, headache by 11.3% versus 1.9% and vomiting by 4.8% versus 0.2%. The label warns of a temporary rise in blood pressure and fall in heart rate after each dose, darkening of the gums and of skin on the face and breasts, and nausea that can be severe.

    What the evidence does not cover: All trial participants were women, and about 86% were White, so the FDA notes that results for other groups cannot be fully assessed. The approval is for one indication in one population. It does not establish benefit in men or in other situations, and it says nothing about unregulated products sold under the same name.

    Grade (suggested, adjust to your scale): A for the approved indication only.

    Melanotan II: an old small study and a record of warnings

    What it is: A synthetic melanocortin analogue originally studied for tanning. It is not approved by the FDA for any use.

    Evidence: The human sexual-function data come largely from a small double-blind, placebo-controlled crossover study published in 2000 (Wessells and colleagues, International Journal of Impotence Research). In 20 men with erectile dysfunction, 17 had erections without sexual stimulation, and increased desire was reported after 13 of 19 doses versus 4 of 21 placebo doses. Nausea and yawning were the most frequent side effects, and about 13% had severe nausea at the higher dose tested. The authors called for more investigation. That study is more than 25 years old, small, and short.

    Safety record: The Skin Cancer Foundation, in a July 2026 statement, discouraged the use of melanotan II and other unapproved tanning agents, citing published case reports of melanoma, rapid changes in moles, systemic toxicity and muscle damage. The Foundation says case reports cannot establish causation, and the full short- and long-term effects are unknown. The UK’s MHRA has said for years that melanotan products sold there are unlicensed and have not been tested for safety, quality or effectiveness.

    Grade (suggested): C or lower. A 2000 pilot study is not a basis for confidence, and the safety signals are real.

    Kisspeptin: intriguing biology, no clinical case yet

    What it is: A naturally occurring peptide that sits near the top of the reproductive hormone cascade.

    Evidence: A 2017 placebo-controlled crossover study in JCI Insight gave intravenous kisspeptin-54 to 29 healthy heterosexual men, aged about 25, while they underwent brain imaging and viewed sexual, couple-bonding, negative and neutral images. Kisspeptin increased activity in some brain regions involved in sexual and emotional processing, and the size of one reward-region response correlated with lower sexual aversion scores. It raised luteinizing hormone but did not change testosterone, oxytocin or cortisol.

    What it does not show: The authors list their own limits: a small sample of young heterosexual men, intravenous dosing that does not mimic natural pulsatile release, correlational links between brain activity and questionnaires, and significant effects in only some regions. The study measured brain responses, not sexual function or any clinical outcome. The authors suggest future research in reproductive disorders and in psychosexual problems, and they say so as a possibility, not a finding. A brain-imaging result in healthy volunteers is not evidence that a product will help anyone.

    Grade (suggested): C. Early human physiology.

    Oxytocin: a lot of research, little of it on sexual function

    What it is: A hormone and neuropeptide best known for roles in labor, lactation and social bonding.

    Evidence: A 2021 systematic review in Sexual Medicine (Cera and colleagues) looked at whether blood or saliva oxytocin levels track sexual arousal and orgasm. It included 13 studies, about 325 participants in total, published between 1969 and 2019, with varied designs. Most found oxytocin higher around orgasm or ejaculation, while the arousal findings were mixed. The authors call their hypotheses tentative and ask for standardized stimuli and objective measures of arousal.

    Important limit: That review excluded studies of intranasal oxytocin. It tells us how the body’s own oxytocin behaves, not whether a nasal spray improves sexual function, and I did not verify the results of intranasal treatment trials for this piece. Higher oxytocin during sex does not mean taking oxytocin improves sex.

    Grade (suggested): C for any sexual-function claim.

    What is being studied now

    Nothing new has emerged as a late-stage peptide drug for sexual function that I could find. The current activity is mostly new uses and mechanism work for bremelanotide, plus early research on other peptides.

    • Bremelanotide for men, combined with an erectile dysfunction pill. In June 2024, Palatin announced an open-label phase 2 study of bremelanotide co-administered with a PDE5 inhibitor, planned for about 50 men whose erectile dysfunction did not respond adequately to a PDE5 inhibitor alone. The company said topline data were expected by the end of 2024. I found no reported results, so whether the study finished, and what it found, is unknown. This is company information, not a published result.
    • How bremelanotide may work in women. A 2022 Journal of Clinical Investigation study used brain imaging in 31 premenopausal women with low desire. More women reported increased desire within 24 hours after the drug than after placebo (21 versus 8), and the authors suggest the drug may reduce self-consciousness during sexual stimulation. It was funded by the drug’s manufacturer, tested single doses, and studied only premenopausal heterosexual women, so it is a mechanism study, not new proof of benefit.
    • Another bremelanotide trial. A phase 3 bridging trial in premenopausal women with HSDD is registered on ClinicalTrials.gov (NCT04943068). We could not retrieve its details, so we cannot say who is running it, where, or its status.
    • Kisspeptin and oxytocin. We found no newer human trials for sexual function beyond the work described above. Absence of a result in our search is not proof none exist; check ClinicalTrials.gov before citing.

    The pattern is worth noticing: the compounds with the most credible activity are ones already studied in controlled trials, and the research-chemical “next generation” products promoted online usually have no trial behind them at all.

    Common claims, and what the evidence supports

    Claim you may seeWhat the evidence shows
    “PT-141 is FDA approved.”True for one indication in premenopausal women with HSDD. It does not cover other uses or other people.
    “Clinically proven to boost desire.”The approved drug showed a small average improvement over placebo in one population, with frequent nausea and flushing.
    “Melanotan II treats ED.”A 20-man study from 2000 showed erections. It is old and small, and safety concerns are documented.
    “Kisspeptin improves libido.”A brain-imaging study in 29 healthy men. No clinical outcome.
    “Oxytocin boosts arousal.”Body oxytocin rises around orgasm in several studies. That does not show a supplement works.
    “Pharmaceutical-grade, tested for purity.”A claim about a product, not about the compound. Ask for a certificate tied to the lot, and see our coverage of why a single purity number can mislead.

    Where the research-chemical market fits

    The gap between the approved drug and the products sold online is the main point. Vyleesi comes from a manufacturer that ran controlled trials and submitted to FDA review. A vial sold as “PT-141” or “melanotan” online has no such record. Its identity, purity and sterility are whatever the seller and a testing lab say. As covered in our recent Top 10, third-party testing results on the same product can differ widely between labs, and a large preprint found wide variability across vendors. Research-use-only labeling does not change the clinical evidence. A recent Peptides Weekly review summarizes US rules as treating intended use as what matters, with research-use-only wording not overriding evidence of marketing for human use; check FDA’s own guidance before relying on that.

    What to take from this

    • Ask which compound a claim is about, and what kind of evidence sits behind it: an approved-drug trial, a small early study, a brain scan or an animal result.
    • Check the population. Evidence in premenopausal women does not carry over to men, and a study in healthy men does not carry over to anyone with a condition.
    • Treat side-effect data as part of the evidence, not an afterthought. In the bremelanotide trials, nausea affected roughly four in ten women on the drug.
    • Treat sexual-health concerns as medical questions for a licensed clinician. This article is not medical advice, a recommendation to use any compound, or a guide to sourcing one.

    Evidence note: Bremelanotide data come from the FDA’s trial summary, not the full label. The melanotan II trial, the kisspeptin study and the oxytocin review were read through summaries and abstracts as available, not as full papers. I did not verify the compounding status of any of these four in the US, so check the FDA’s current lists before citing it. Safety statements about melanotan II come from case reports and advocacy or regulator warnings, which show concern but not cause.

    Sources:

  • “GLP” Field Guide Part 2: The Approved “GLP”-Class Drugs, Graded

    “GLP” Field Guide Part 2: The Approved “GLP”-Class Drugs, Graded

    Six A’s, two you can’t buy, one that isn’t a peptide. What the grade tells you, and what it doesn’t.

    Peptide Briefs · · Troy Snyder, Ed.D., MBA

    The field guide covered the pipeline. This is the other half of the map: the GLP-class drugs that have already been through a regulator, plus the one combination sitting on the FDA’s desk right now. Seven compounds, each graded the same way the rest of the library is graded. A means peer-reviewed pivotal trials plus a completed regulatory safety review; B means peer-reviewed phase 3 or strong phase 2 without a regulator’s sign-off.

    Six of the seven are A’s, and that is the point of writing them up. An A is not a recommendation and it is not a claim that the drug is the best in its class. Exenatide is an A and has been pulled from the US market. Lixisenatide is an A and was discontinued because nobody wanted it. The grade says the evidence is complete and reviewed. What you do with that is a different question.

    Each section below is short on purpose. These are the best-documented drugs in the entire library, and the full trial records run to hundreds of papers each. I’ve pulled the pivotal trial, the cardiovascular outcomes trial where one exists, the approval history, and the caveat that matters most. Full compound pages will follow for the ones people actually search for.

    Semaglutide

    Evidence grade: A · Also known as Ozempic, Wegovy, Rybelsus; GLP-1 S on some vendor menus.

    What it is. A once-weekly GLP-1 receptor agonist, 31 amino acids, with a C18 fatty diacid on lysine 26 that binds albumin and gives it a half-life of about a week. The oral form uses an absorption enhancer (SNAC) and a much higher dose to get across the stomach wall.

    Why it’s an A. The STEP program (STEP 1, NEJM 2021: 14.9% weight loss at 68 weeks versus 2.4% placebo in 1,961 adults) and the SUSTAIN program for diabetes are peer-reviewed. SELECT (NEJM 2023; 17,604 adults with cardiovascular disease and no diabetes) showed a 20% reduction in major adverse cardiovascular events, the first time an obesity drug did that. FLOW (NEJM 2024) showed kidney protection in type 2 diabetes. The FDA has reviewed all of it: Ozempic for diabetes (December 2017), Rybelsus oral for diabetes (September 2019), Wegovy for obesity (June 2021), cardiovascular risk reduction (March 2024), MASH (August 2025), and the oral Wegovy 25 mg pill (December 22, 2025, based on OASIS 4: 16.6% at 64 weeks).

    Caveat. The gastrointestinal burden is real (74% of STEP 1 participants versus 48% on placebo) and weight returns when treatment stops: the STEP 1 extension showed two-thirds of lost weight regained within a year off drug. Loss of lean mass is a live research question. Semaglutide is also the most counterfeited drug in this class; the FDA stated in June 2026 that sales of unapproved semaglutide products to consumers are illegal, and research-use-only labeling does not change that.

    Key references. Wilding JPH et al., STEP 1, N Engl J Med 2021;384:989 (PMID 33567185). Lincoff AM et al., SELECT, N Engl J Med 2023;389:2221 (PMID 37952131). Marso SP et al., SUSTAIN-6, N Engl J Med 2016;375:1834 (PMID 27633186). Wharton S et al., OASIS 4, N Engl J Med 2025 (PMID 40934115).

    Tirzepatide

    Already has its own page: Tirzepatide (A). Listed here for completeness of the baseline.

    Liraglutide

    Evidence grade: A · Also known as Victoza, Saxenda; generic liraglutide.

    What it is. A once-daily GLP-1 receptor agonist with a C16 fatty acid on lysine 26, half-life about 13 hours. The direct ancestor of semaglutide: same strategy, shorter tail.

    Why it’s an A. SCALE Obesity and Prediabetes (NEJM 2015; 3,731 adults) showed 8.0% weight loss at 56 weeks on 3.0 mg versus 2.6% placebo. LEADER (NEJM 2016; 9,340 adults with type 2 diabetes) showed a 13% reduction in major cardiovascular events and a 22% reduction in cardiovascular death, which made liraglutide the first GLP-1 with a cardiovascular indication (2017). FDA approvals: Victoza for diabetes (January 2010), Saxenda for obesity (December 2014), pediatric diabetes (2019), pediatric obesity (2020). Generic Victoza was approved in December 2024 (Teva, Hikma) and generic Saxenda in August 2025 (Teva), the first generic GLP-1 for weight management.

    Caveat. Daily injection, and the weight loss is roughly half of semaglutide’s in head-to-head data (STEP 8: 15.8% versus 6.4%). A 2024 analysis flagged bone-density declines in Saxenda-treated patients. It matters now mostly because it is the cheapest approved GLP-1 in the US and the one most likely to be substituted for an off-label or compounded product.

    Key references. Pi-Sunyer X et al., SCALE, N Engl J Med 2015;373:11 (PMID 26132939). Marso SP et al., LEADER, N Engl J Med 2016;375:311 (PMID 27295427). Rubino DM et al., STEP 8, JAMA 2022;327:138.

    Dulaglutide

    Evidence grade: A · Also known as Trulicity.

    What it is. Two GLP-1 analogue chains fused to a modified human IgG4 Fc fragment, which is why it is dosed weekly and why it is technically a fusion protein rather than a lipidated peptide.

    Why it’s an A. The AWARD program established glycemic efficacy; FDA approval for type 2 diabetes came in September 2014. REWIND (Lancet 2019; 9,901 adults, median 5.4 years, the longest GLP-1 outcomes trial) showed a 12% reduction in major cardiovascular events in a population that was mostly primary prevention, which earned a cardiovascular indication in February 2020 covering both people with and without established heart disease. Weight loss is modest: about 1.5 kg in REWIND, 4 to 5 kg at the higher 3.0 and 4.5 mg doses in AWARD-11.

    Caveat. It is a diabetes drug, not an obesity drug, and has never been submitted for weight management. Anyone marketing it as a weight-loss peptide is working from the wrong trial record. Not available as a generic.

    Key references. Gerstein HC et al., REWIND, Lancet 2019;394:121 (PMID 31189511). Frias JP et al., AWARD-11, Diabetes Care 2021;44:765.

    Exenatide

    Evidence grade: A · Also known as Byetta, Bydureon, Bydureon BCise; exendin-4.

    What it is. The original. A 39-amino-acid peptide first isolated from Gila monster venom, about 53% identical to human GLP-1 and resistant to DPP-4 breakdown, with a half-life of about 2.4 hours. Byetta was twice-daily; Bydureon wrapped it in microspheres for weekly dosing.

    Why it’s an A. FDA approval in April 2005 made it the first GLP-1 receptor agonist on the market. The AMIGO trials established glycemic control; Bydureon (weekly) followed in 2012. EXSCEL (NEJM 2017; 14,752 adults) showed cardiovascular safety (non-inferiority) but not benefit, with a hazard ratio of 0.91 that just missed significance.

    Caveat. This is an A for a drug you can barely buy. AstraZeneca discontinued Byetta and Bydureon BCise in the US in October 2024 as a business decision; Amneal’s generic exenatide (Byetta equivalent) was approved in November 2024 and is the only form still sold. Weight loss was never the point: 2 to 3 kg in the diabetes trials. It belongs in the library because the entire class descends from it and because it still turns up on research vendor menus at prices that make no sense for a drug with an approved generic.

    Key references. Holman RR et al., EXSCEL, N Engl J Med 2017;377:1228 (PMID 28910237). DeFronzo RA et al., AMIGO, Diabetes Care 2005;28:1092.

    Lixisenatide

    Evidence grade: A · Also known as Adlyxin (US), Lyxumia (EU); the lixisenatide half of Soliqua.

    What it is. A once-daily exendin-4 derivative with a C-terminal polylysine tail, 44 amino acids, short-acting. Its distinguishing feature was a strong effect on post-meal glucose through gastric emptying, with less effect on fasting glucose.

    Why it’s an A. GetGoal program for glycemic control; FDA approval July 2016. ELIXA (NEJM 2015; 6,068 adults after an acute coronary event) showed cardiovascular safety but no benefit, hazard ratio 1.02.

    Caveat. Sanofi discontinued standalone Adlyxin in the US effective January 1, 2023, citing competition and poor sales; it survives only inside Soliqua (with insulin glargine). Weight effect was minimal, around 1 kg. Grade A, commercially dead. If a vendor is listing it, ask what possible research question it answers that liraglutide does not.

    Key references. Pfeffer MA et al., ELIXA, N Engl J Med 2015;373:2247 (PMID 26630143).

    Orforglipron

    Evidence grade: A · Also known as Foundayo. Not a peptide.

    What it is. A once-daily oral small molecule that activates the GLP-1 receptor. Discovered by Chugai, licensed to Lilly in 2018. Because it is not a peptide it has no absorption problem, no food or water restrictions, and cannot be made by peptide synthesis; it belongs in this library only because readers will see it next to the peptides everywhere else.

    Why it’s an A. ATTAIN-1 (NEJM 2025; 3,127 adults without diabetes, 72 weeks) showed 12.4% weight loss at the top dose if everyone adhered, 11.1% on the treatment-regimen estimand, versus 2.1% placebo. ATTAIN-2 covered type 2 diabetes. The FDA approved it for chronic weight management on April 1, 2026, 50 days after filing under the national priority voucher program; diabetes is a separate pending submission. UK authorization followed in 2026.

    Caveat. It loses to every injectable on the scale: roughly half of tirzepatide’s effect and below oral Wegovy’s 16.6%. Nausea ran 29 to 36% versus 10% on placebo, and the approved dose ladder (0.8 to 17.2 mg) differs from the trial’s titration without a published explanation. No cardiovascular outcomes data yet. Boxed thyroid warning like the rest of the class.

    Key references. Wharton S et al., ATTAIN-1, N Engl J Med 2025;393:1796 (doi 10.1056/NEJMoa2511774). FDA approval announcement, April 1, 2026.

    CagriSema

    Evidence grade: B · Cagrilintide 2.4 mg plus semaglutide 2.4 mg, once weekly, one pen.

    What it is. A fixed-dose combination of an amylin analogue and a GLP-1 analogue, two separate peptides co-formulated. Each half has its own page or will shortly: cagrilintide (B) is live; semaglutide is above.

    Why it’s a B and not an A. The pivotal trials are peer-reviewed: REDEFINE 1 (NEJM 2025; n = 3,417) showed 20.4% weight loss at 68 weeks, 22.7% if everyone adhered, versus 3.0% placebo; REDEFINE 2 (NEJM 2025; type 2 diabetes) showed 13.7%. But no regulator has finished a review. Novo Nordisk filed with the FDA on December 18, 2025 and has guided to a decision in the fourth quarter of 2026. REDEFINE 4, the open-label head-to-head against tirzepatide 15 mg, missed its non-inferiority endpoint in February 2026 (20.2% versus 23.6% at 84 weeks). The cardiovascular outcomes trial (REDEFINE 3) is ongoing.

    Caveat. Four in five participants had gastrointestinal side effects. Only 57% of the REDEFINE 1 CagriSema group reached the top dose under a flexible protocol, which the sponsor cites as context for the tirzepatide miss and critics read the other way. A higher-dose version (2.4/7.2 mg) starts phase 3 in the second half of 2026. This grade changes the day the FDA rules; watch Grade Changes.

    Key references. Garvey WT et al., REDEFINE 1, N Engl J Med 2025 (doi 10.1056/NEJMoa2502081). Davies MJ et al., REDEFINE 2, N Engl J Med 2025 (doi 10.1056/NEJMoa2502082). Novo Nordisk, REDEFINE 4 announcement, February 23, 2026.

    What the baseline tells you

    Three things stand out when the approved drugs are lined up this way.

    First, the A grade is about evidence, not usefulness. Two of the six A’s are discontinued, one was never a weight-loss drug, and one isn’t a peptide. If you are reading this library to decide which compound is interesting, the grade is the floor, not the answer.

    Second, the cardiovascular outcomes trials are the real dividing line inside the A’s. Liraglutide, semaglutide and dulaglutide showed benefit. Exenatide and lixisenatide showed safety only. That difference, more than the weight numbers, is why the first three dominate prescribing.

    Third, every pipeline compound in the field guide is measured against this table. UBT251’s 19.7% at 24 weeks is impressive because tirzepatide’s 72-week number is about 21%. Survodutide’s 13% is underwhelming because semaglutide’s is 15%. The baseline is what makes the pipeline numbers mean anything.

    Peptide Briefs is an independent reference and does not sell anything. Its owners co-own a research-peptide vendor; that is disclosed on every page. Nothing here is medical advice or a dosing recommendation.

  • 12 Websites Every Peptide Researcher Should Bookmark + 88 More Worth Knowing

    12 Websites Every Peptide Researcher Should Bookmark + 88 More Worth Knowing

    The tools I actually use to check claims, read the evidence and keep up with the rules.

    Originally Shared on Substack

    Most of us visit the same few websites every day. Meanwhile, some of the most useful tools on the internet sit unused. When I started reading about peptides, I learned fast that the quality of what you find depends on where you look. A good source takes a claim apart. A bad one just repeats it.

    Subscribe for free to receive new posts and support my work.

    Subscribe

    Here are the 12 I would bookmark first, and why. The full list of 100 is below.

    The evidence

    1. PubMed. The main search engine for biomedical research. Search a compound name and look at what is actually published, then notice how much is animal or cell work.

    2. ClinicalTrials.gov. Shows which human trials are registered, running or finished. If a compound has no trials here, that tells you something.

    3. Cochrane Library. Systematic reviews that pool many studies. Slow and careful, which is the point.

    4. DailyMed. Official labels for approved drugs. Useful for seeing what regulators allow a drug to claim.

    The rules

    5. Federal Register. Where proposed and final policy appears. Good for reading the notice itself instead of a headline about it.

    6. Regulations.gov. Where public comments are filed. You can read what others have said and submit your own.

    7. FDA.gov and Drugs@FDA. What is approved, for what, and what has received warnings.

    The truth check

    8. Wayback Machine. See what a company claimed last month, or last year.

    9. Google Fact Check Explorer. Search a claim and see who has already examined it.

    10. Retraction Watch. Tracks retracted papers. A study can look strong right up until it is withdrawn.

    The quick references

    11. Examine.com. Plain language summaries of supplement and nutrition research.

    12. Our World in Data. Clear charts built from real datasets, handy when a post throws out a statistic.

    A note on what none of these do. Reading a paper is not a prescription, and finding a study is not proof something works for you. Several of these sites exist to help you see how thin the evidence can be. That is a feature.

    The full list of 100

    Research and evidence: PubMed, ClinicalTrials.gov, Cochrane Library, Google Scholar, Semantic Scholar, Europe PMC, DailyMed, Drugs@FDA, DrugBank, Retraction Watch

    Policy and regulation: Federal Register, Regulations.gov, FDA.gov, HHS.gov, Congress.gov, SEC EDGAR, USPTO, FTC.gov, Your State’s Secretary of State Page (Colorado for me), CBP.gov

    Verifying things: Wayback Machine, ICANN Lookup, VirusTotal, urlscan.io, Have I Been Pwned, Snopes, Google Fact Check Explorer, TinEye, Archive.today, OpenCorporates

    Web and SEO: Google Search Console, Google Analytics, Google Trends, Bing Webmaster Tools, PageSpeed Insights, Ahrefs Webmaster Tools, AnswerThePublic, SimilarWeb, Schema.org, W3C Validator

    Store and operations: WooCommerce docs, WordPress.org, Stripe, Klaviyo, Zapier, Cloudflare, Canva, QuickBooks, Shippo, Wise, Omnisend

    Writing and publishing: Substack, Hemingway Editor, Grammarly, Notion, Linktree, Beehiiv, Ghost, Typeform, Calendly, Loom

    Learning: Khan Academy, Coursera, edX, MIT OpenCourseWare, Wikipedia, Project Gutenberg, Library of Congress, Our World in Data, TED, Wolfram Alpha

    Health references: MedlinePlus, Mayo Clinic, CDC, NIH, WHO, Examine.com, Cleveland Clinic, USDA FoodData Central, Cronometer, NHS

    News and analysis: Reuters, AP News, Axios, STAT News, Endpoints News, Fierce Biotech, Time, Financial Times, ProPublica, BBC News

    My Other Everyday Sites: Weather.gov, Google Flights, Recreation.gov, Colorado Parks and Wildlife, onX Hunt, Rome2Rio, iNaturalist, Kelley Blue Book, CarGurus, Google Maps

    Pick five that solve a real problem for you and ignore the rest. You will remember those.

    Peptide Briefs is an independent educational library. Nothing here is medical advice.

    Disclosure: we co-own a research-peptide vendor. Peptide Briefs is written independently of it and does not link to it.

  • Funny, Strange and Scary Stories From Inside the Chinese Peptide Supply Chain

    Funny, Strange and Scary Stories From Inside the Chinese Peptide Supply Chain

    Origiannly Posted on Substack

    A reader asked for the stories behind my China article, so here are some. I went back through my own conversations with sellers there. I have left out names, companies, phone numbers, addresses, and prices. These stories describe my dealings with sellers in China and nothing else. They say nothing about any supplier in the United States.

    Subscribe

    Discovering My First Supplier: A Journey Through Reddit and Shenzhen Sea World

    Finding my very first supplier in China was an unexpected adventure that unfolded in the most unconventional way – on Reddit! It wasn’t through a factory visit or a bustling trade show; it was through connecting with a fascinating individual with a unique story.

    This particular supplier was living in Shenzhen and originally hailed from Nigeria. He specialized in peptides, which piqued my interest right away. However, I must admit that my initial reaction was laced with apprehension. Selling injectables over the internet can certainly raise red flags, and I had to confront the unfair stereotypes about online scams, particularly those related to Nigeria. The stereotype isn’t just a perception; it can cloud judgment. Instead of focusing on his nationality, I realized I needed to assess the situation more objectively.

    I looked for a way to reassure myself about his authenticity and found that he had shared photos of himself at a well-known spot in Shenzhen called Sea World—somewhere I recognized because I had been there myself! While this didn’t definitively prove his credibility or the quality of his products, it created a sense of connection. It turned him from a faceless stranger into someone who lived just an hour away by ferry, making the whole situation feel more tangible.

    This small but meaningful verification taught me an important lesson about the market. Peptides often pose sourcing challenges in China because they’re intended for export. Domestic sales are generally discouraged, which means that sometimes it’s easier for a foreigner on Reddit to find reputable suppliers than to locate a lab nearby. As I explored further, I discovered additional vendors on Meituan, a Chinese shopping app. This was a whole new experience—products were cleverly disguised as skincare, and titles contained deliberate misspellings, adding an element of intrigue.

    Looking back, it’s clear that my first supplier was more of a trader than a direct manufacturer. This is a crucial distinction I now emphasize to anyone entering this field. At that time, all I knew was that he felt authentic enough for me to want to meet him in a place I recognized.

    * Bacteriostatic water in China comes in ampoules. You then have to use a filter needle to make sure you don’t get glass fragments into the injectable liquid. I never got comfortable with it and brought my own.

    Navigating Sterile Standards and Visitor Restrictions

    Out of the blue, I received a message from a salesperson representing a factory that boldly claimed to be a leading peptide manufacturer. They promised 99% purity, certificates of analysis, no minimum order, and readily available stock. Exciting, right? I was eager to learn more, so I asked if I could visit their facility.

    The response was somewhat surprising: they only catered to VIP clients, and their factory maintained strict sterile production standards. I was invited to place a small trial order instead. Here’s my takeaway: they were too sterile for a visitor but open to selling to unknown strangers. I followed my learned principle: factories that welcome visits are typically genuine producers, while those that impose visitor restrictions can raise concerns. With that, I respectfully declined their offer.

    Let Me Consult My Boss Tomorrow

    I reached out to another factory, repeating my inquiry about visiting. The representative assured me she would check with her boss the following day. I inquired about their testing procedures, but the answer was vague—“third-party independent laboratory testing.” No specifics, just a general term.

    Later that day, the narrative shifted. Suddenly, they were open to visits, but only for clients placing large orders. Did I want to see factory videos first? While video tours are nice, they don’t equate to an actual visit. I’m looking for transparency, not a promotional trailer.

    The Three Bosses

    The most welcoming response came from a representative at a different company. She enthusiastically suggested that I inspect their site since I was nearby, even embracing my idea of organizing a tour group for sellers. However, before she could approve a visit for a friend, she inquired if he was American. Spoiler alert: he was. I’ll let you draw your own conclusions.

    A few days later, I received an update from her. After some “deliberation among our three bosses,” the directive changed. I was now required to place a sample order, send it for testing, and only then would they consider a site visit. If the product failed the test, I would be fully refunded; if it passed and I was willing to endorse their company, they would refund 30% of the testing fee.

    Take a moment to ponder that. What began as an invitation to visit morphed into a transaction, and that testing fee was essentially a discount tied to a potential testimonial. It felt wholly inappropriate to me. A lab test should genuinely reflect the quality of a product and shouldn’t be contingent on my willingness to provide a positive review.

    Communicating Clearly with a Language Barrier

    Navigating the language differences in this business can be quite a challenge. One seller listed a popular weight-management compound, but their product name included periods between syllables, which I suspected was a deliberate attempt to bypass keyword filters. When I inquired about product sizes, I was encouraged to send my request “in the straightest way possible”—a testament to the challenges of translation tools.

    Then came a memorable moment when I asked about a blend humorously referred to as “Wolverine” in online communities. The response informed me that only peptide injections were available. Clearly, the nickname had lost its charm in translation! I had to clarify, quite politely, that I wasn’t actually ordering a superhero.

    The Batch That Turned to Gel

    In my quest, one product from an early order didn’t behave as expected; it clumped together and transformed into a gel. I tried various solutions—acetic acid, bacteriostatic water, and even sought out glycerol. Unfortunately, I lost three vials in the process.

    The seller advised me to experiment with different types of water and asked for my feedback. When that didn’t yield the desired results, she offered either a replacement or a refund.

    This journey of discovery, intertwined with both challenges and triumphs, opened my eyes to the complexities of international trade and the importance of forging authentic relationships in the business world. It’s this process of learning and adaptation that fuels my enthusiasm for what lies ahead as I continue to explore and grow in this vibrant market!

    The Domestic Lists

    I said earlier that the industry is built around exports. That is true of the sellers who message foreigners. But it is not the whole picture.

    At some point a different kind of spreadsheet reached me: a price list for the domestic market. Same idea as the export menu, but with a twist. It had one column for a brand or street name and another column for the real name of what was inside.

    That extra column tells you a lot. Products were sold under nicknames and invented brands, and the “real name” column was there so buyers knew what the nickname meant. The list mixed peptides with other bodybuilding products, which tells me who the customer is: gym-goers, not skincare shoppers.

    One brand name on it borrowed the name of a well-known approved weight-management drug and added “pen type.” That is not a brand. That is a costume.

    Then there was the pricing. Early on, the domestic list charged noticeably more than the export menu. In one case, a single vial on the domestic list cost more than a whole box of ten on the export sheet. I do not know why. Different sellers, different margins, retail versus wholesale, or a premium for risk are all possible, and I cannot tell you which. Later on, the domestic list became much cheaper, especially factoring in shipping costs, than the export lists, like about 25% cheaper across the board, and shipping was less than $10.

    Two cautions. I do not know who produced this list, how current it was, or whether anyone could actually deliver at those prices. And a list is not a sale.

    But it settles one thing for me. The seller who told me this product is not legally available in China was right about the law. She was not saying nobody buys it there.

    Lab Visits

    This is actually the boring section of this article. I visited 3 labs while living in China. The ones I saw were professional, clean, and respectable. They had assembly lines that appeared sterile, and workers wore lab coats, gloves, and masks and actively monitored the lines. They also had labs with state-of-the-art-looking equipment to check products. I saw nothing that caused alarms, but again, they also had nothing to hide.

    I assume the ones that denied my visit were hiding their operations, if they were even labs and not just bulk-powered buyers and vial fillers.

    What I took away

    Ask to visit. A real producer usually says yes. Treat a no, a delay, or a new condition as information.

    Test the product, not the paperwork. “COA provided” is the cheapest sentence in this industry.

    A relationship is not verification. Months of friendly messages did not make a vial what its label said.

    Test every lot with an independent lab, and compare reports from more than one.

    This article describes my own experience with sellers in China. It is not medical advice, and none of the products discussed here are approved for the uses people claim online.

    Share

    Disclosure: I co-own a research-use-only peptide business. Peptide Briefs runs independently of it. This is not medical advice.

  • The FDA’s Six, Part 3: HHS Cleared the Six. Here Is What That Does and Does Not Mean

    The FDA’s Six, Part 3: HHS Cleared the Six. Here Is What That Does and Does Not Mean

    Originally publshed on Substack

    Today the Department of Health and Human Services published an interim policy in the Federal Register covering six peptides: BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. Under it, FDA says it will not take enforcement action against licensed 503A pharmacies and physicians who compound these peptides for individual patients, provided they meet conditions on ingredient quality, manufacturing standards, labeling, safety reporting and patient-specific prescriptions. Several clinicians are reporting an effective date of Friday, October 30.

    Subscribe

    This is the end of a road that started in September 2023, when FDA moved these compounds into Category 2 of its interim bulks policy, effectively blocking pharmacies from compounding them. In April 2026 they were removed from Category 2. In July an FDA advisory committee voted narrowly, 8 to 6 on most of them, to recommend adding all six to the 503A bulks list, over the objection of the agency’s own scientific reviewers. On October 14 HHS sent this interim policy to the White House. It cleared review on October 27 and was published today.

    What it is

    Enforcement discretion. FDA is telling compounding pharmacies it will not pursue them for making these six, as long as the conditions are met. That gives clinics and telehealth providers a workable federal basis to prescribe them for the first time in three years.

    What it is not

    Approval. HHS said explicitly that the policy does not constitute FDA approval of the peptides or of any compounded product made from them. Compounded drugs are not reviewed for safety, efficacy or quality before they reach patients. HHS also said it may reconsider the policy if safety signals or product-quality problems emerge, which is a reminder that this can be withdrawn as easily as it was granted.

    It also does not bind the states. State boards of pharmacy regulate compounding on the ground, and at least one industry figure has already said some states may not follow the federal move.

    And it does not touch research-use products. A vial sold as research-use-only is outside a compounding policy entirely. Nothing in today’s announcement changes the legal status of that market in either direction.

    What the evidence says

    Here is the part that matters most to this library. FDA’s reviewers found no human safety studies for KPV, TB-500, MOTS-c or Epitalon, and found the BPC-157 trials too small and too short to establish safety or efficacy for any proposed use. An independent systematic review published this month in Acta Orthopaedica Belgica searched every major database through June for human BPC-157 data and came to a similar conclusion.

    So the grades here do not move. BPC-157 stays at C. TB-500 stays at C. The others hold where they are. A policy decision about who may dispense a compound is not evidence about whether it works, and this library grades evidence.

    What to watch

    The policy text itself, which should show exactly which conditions pharmacies must meet and whether specific indications are named. Any state board responses. The citizen petition filed last week asking FDA to block compounding of these peptides. And, further out, whether FDA ever starts the formal rulemaking that would put any of the six on the bulks list permanently. The advisory committee’s recommendation was non-binding, and as of today no proposed rule exists.

    Disclosure: I co-own a research-peptide vendor. That is disclosed on every page of this publication and does not affect how compounds are graded here.

    Sources
    Reuters, Oct 28, 2026: US health department to allow temporary sale of some unapproved peptides
    AJMC, Jul 31, 2026: FDA Panel Backs 6 Peptides for Compounding
    Holland & Knight, Oct 2026: Peptides at a Crossroads
    reginfo.gov, RIN 0910-ZD94, Interim Access Policy for Compounding Using Certain Peptides

  • WHAT ACTUALLY HAPPENS TO A PEPTIDE BEFORE IT REACHES THE VIAL

    WHAT ACTUALLY HAPPENS TO A PEPTIDE BEFORE IT REACHES THE VIAL

    Eight steps, and where each one can go wrong.

    A label says “99% pure.” It doesn’t say what happened before that number. Here is the path of one lot from chemistry to certificate, with the question to ask at each step.

    This is about manufacturing and testing. It is research-use-only information, not guidance for use in people.

    A note on where this comes from. I spent two years living in China, where I observed the peptide industry up close: I met vendors and manufacturers and visited their labs. I’m not a chemist, and this post doesn’t pretend to be a lab manual. It’s what I learned about how a lot moves from synthesis to certificate, and about which questions separate a real certificate from a PDF.

    SYNTHESIS
    Amino acids are joined one at a time on a resin bead. No step is perfect.
    Make Simple: at 99% efficiency per step, a 30-amino-acid peptide comes out roughly three-quarters full-length. The rest is near-miss sequences.
    Ask: how was the batch made, and how was the crude product cleaned up?

    CLEAVAGE
    The chain is chemically cut from the resin. What comes off is a mixture: the target, truncated pieces, deleted sequences, leftover reagents.

    PURIFICATION
    Preparative HPLC separates the target from the junk. Which fractions get kept is a judgment call, and it sets the final purity.

    FREEZE-DRYING
    The purified peptide is freeze-dried into powder. That powder is not 100% peptide. It also holds water and counterions such as TFA or acetate.
    Make Simple: “net peptide content” tells you how much of the powder is actually peptide.
    Ask: is net peptide content reported?

    PURITY TEST
    Analytical HPLC reports the share of the signal that belongs to the main peak.
    Make Simple: purity tells you how clean. It does not tell you what it is.

    IDENTITY TEST
    Mass spectrometry checks the molecular weight. Without it, a clean peak could still be the wrong molecule.
    Ask: is identity confirmed, and by what method?

    SAFETY TESTS
    Endotoxin and microbial testing are separate from purity. A certificate that lists only HPLC doesn’t cover them.

    THE CERTIFICATE
    A COA is a claim about one lot.
    Check: the lot number matches the vial. The report number can be verified with the lab itself, not just a PDF. The methods are listed. An independent lab ran it. The lab’s accreditation status is stated honestly.THE JOURNEY IN ONE LINE
    Synthesis → cleavage → purification → freeze-drying → purity → identity → safety → certificate

    THE BIG TAKEAWAY
    A single percentage hides seven other steps. Before you trust a COA, ask:

    1. Does it show purity AND identity?
    2. Is net peptide content reported?
    3. Were endotoxin and microbial tests run?
    4. Does the lot match the vial?
    5. Can the report number be verified with the lab?

    Which of these do you see missing most often?

    This post describes general peptide manufacturing and analytical practice. It makes no claim about any specific product or supplier.

    Also published on Substack.

  • The FDA’s Six: What the Human Evidence Actually Shows

    On July 23-24, 2026, something unusual happened at the FDA’s White Oak campus. The Pharmacy Compounding Advisory Committee, a panel that exists to give the agency outside expert advice, voted against FDA staff’s own written recommendations six times in a row. Reporters in the room described an audible gasp when the first tally was read.

    The result: BPC-157, TB-500, Semax, KPV, MOTS-c, and Epitalon all received committee recommendations for inclusion on the FDA’s 503A Bulks List, the mechanism that lets licensed compounding pharmacies legally prepare patient-specific prescriptions. A seventh compound, Emideltide (DSIP), was voted down.

    This is not FDA approval. It’s not even a final decision. It’s a non-binding recommendation, and as of this writing, two months later, the FDA hasn’t acted on it. Formal rulemaking, if it happens, typically takes 8-12 months.

    But the vote raises a question worth answering properly: what does the actual human evidence say about these six compounds? Not the mechanism papers, not the mouse studies people cite as if they settle the matter. The human data specifically. Here’s the honest picture, compound by compound.

    BPC-157

    Grade: D. Plausible mechanism, essentially no human evidence.

    BPC-157 has zero completed human randomized controlled trials. That’s the single fact that matters most here, and it’s worth sitting with before anything else.

    The closest thing to human-scale data is a recent retrospective count of 1,039 documented users, tracked from nadir to follow-up. That’s a real number, but it measures something different than most people assume: it tells you how many people used the compound, not whether it worked. A usage count and an efficacy result are two different questions, and conflating them is the most common error in how this compound gets discussed.

    The clinical history is also more instructive than most coverage lets on. The original research trail goes back to PLIVA, the Croatian pharmaceutical company that worked with discoverer Predrag Sikiric. PLIVA registered early-stage trials around 2000 that were never published. The research was sold to GSX in 2006, and GSX abandoned it. A separate trial in Tijuana in 2015 was also canceled with no data released. Multiple companies with real resources picked this compound up and walked away. That’s a different story than “suppressed because it works,” but it’s also not nothing.

    TB-500

    Grade: D. Same evidence category as BPC-157.

    TB-500 (a synthetic fragment of Thymosin Beta-4) has an extensive preclinical literature on tissue repair, cell migration, and wound healing. None of it has translated into a completed human clinical trial for the injectable research compound as it’s commonly sold.

    The mechanistic story is genuinely interesting; it’s thought to coordinate the movement of cells involved in tissue repair, which is why it shows up so often in sports medicine and regenerative medicine discussions. But “mechanistically interesting” and “shown to work in humans” remain two separate claims, and only the first one currently has support.

    Semax

    Grade: D, with an asterisk worth understanding.

    Semax has a real research history, just not one that shows up cleanly in a PubMed search. A meaningful share of the literature on Semax (and several other Russian-developed compounds, including some of the older bromantane and actovegin research) exists in Russian-language journals that were never translated or indexed in the databases most Western researchers default to.

    This matters because “no human trials” and “no human trials I can find in English” are different claims, and the discourse around Semax tends to treat them as identical. To be direct about the limits of this caveat: this is a well-documented pattern in the space, and it’s a real gap in how evidence gets surfaced, but it isn’t a claim we’ve personally verified paper-by-paper. Treat it as an important qualifier, not a settled fact that resolves the evidence question in Semax’s favor.

    KPV

    Grade: D. The strongest mechanism of the six, and still zero completed human trials.

    KPV is a three-amino-acid fragment of alpha-MSH, and its mechanism is unusually well-characterized for a compound this size. It enters intestinal and immune cells through the PepT1 transporter, the same carrier that handles dipeptides and tripeptides from digested dietary protein, and once inside, it interferes with the importin-alpha3/p65RelA complex, blocking NF-kB nuclear translocation and suppressing downstream inflammatory cytokines (TNF-alpha, IL-1, IL-6).

    The animal data is genuinely strong: DSS and TNBS mouse colitis models (Dalmasso 2008, Kannengiesser 2008) show meaningful reductions in inflammatory markers. The problem is the translation step. DSS/TNBS mouse colitis models have historically translated to human outcomes at only 10-15%, a sobering number for any compound whose entire efficacy case currently rests on mouse data. Zero completed human RCTs exist for KPV in any indication.

    MOTS-c

    Grade: D. The clearest correlation-vs-causation trap of the six.

    MOTS-c is a 16-amino-acid peptide encoded directly in mitochondrial DNA, discovered in 2015. The animal data (primarily mice) shows real effects on insulin sensitivity, inflammatory markers, and glucose homeostasis.

    The human data that exists is purely observational: exercise increases circulating MOTS-c levels in skeletal muscle and blood. That’s a real finding, but it’s a correlation between exercise and a biomarker, not a controlled trial testing whether giving someone exogenous MOTS-c produces a treatment effect. No published human interventional trial has tested that question. The gap between “your body makes more of this when you exercise” and “taking more of this replicates exercise’s benefits” is exactly the kind of gap that’s easy to paper over with hopeful language, and worth naming directly instead.

    Epitalon

    Grade: D. Same literature-access problem as Semax.

    Epitalon carries a near-legendary reputation in longevity circles, and its research history runs into the same issue as Semax: a real body of work exists, much of it Russian in origin, and much of it sits outside what’s easily searchable in English-language databases. The same caveat applies here as it did for Semax: this is a documented pattern worth naming, not a fully verified claim that resolves the evidence gap.

    The pattern across all six

    Every one of these compounds has a plausible, often well-characterized mechanism. Every one has real preclinical (mostly animal) data supporting that mechanism. And every one is missing the thing that actually determines whether a compound works in people: a completed human clinical trial.

    That’s not a condemnation of any of them. Plenty of compounds with this exact profile eventually clear that bar. It’s just the honest state of the evidence right now, and it’s worth being precise about it independent of the regulatory news cycle.

    Here’s the distinction that matters most going forward: a 503A compounding recommendation, if the FDA eventually adopts it, changes the legal pathway for these compounds. It does not change the evidence. Those are two separate axes, and it’s worth not letting a genuinely significant regulatory story get mistaken for a medical one.

    We’ll keep grading these as the literature moves. If any of the six clears a real human trial, that’s the post that follows this one.

  • What a 60%-Off Sale Actually Tells You About a Peptide Supplier

    Troy Snyder, September 2026

    If you’ve spent any time in peptide research circles this month, you’ve seen it: sitewide discounts stacking past 50%, automatic markdowns on top of promo codes, giveaways for anyone who checks out with the right code. One vendor pairs a 45% automatic discount with another 15% off code and calls it “no end date.” Another runs Buy-One-Get-One on top of a percentage code that, stacked correctly, works out to over 60% off per vial.

    It’s tempting to read that as a good deal. It’s worth reading it as a question instead: how does a business built around third-party testing, verified sourcing, and cold-chain shipping sustain a discount that deep, indefinitely, and still stay in business?

    There are really only three ways the math works.

    One: the margin was never that thin to begin with. If a sitewide “sale” price still covers costs at 60% off, the pre-sale price wasn’t reflecting real costs — it was reflecting what the market would bear before the next promo. That’s not illegal. It’s just worth knowing that “sale price” and “fair price” aren’t the same claim.

    Two: something in the process is getting cut to make the discount work. Third-party testing costs money per batch ($200 to $500 per vial depending on the peptide and tests). Verified cold-chain shipping costs money per order. A cryptographically signed Certificate of Analysis, one you can actually verify yourself, not just a PDF with a lab’s letterhead on it costs more than a basic identity check. When the discount is deep enough and permanent enough, ask which of those got quietly thinned out to protect the margin.

    Three: it’s a customer-acquisition strategy, not a pricing strategy. Giveaways, referral drawings, “round two” prize drawings for anyone who already bought these are list-building and retention plays. Nothing wrong with that on its own. But it means the price you’re looking at was never really about the product. It was about winning your business away from whoever you were buying from before, permanently discounted forever, funded by volume rather than margin.

    None of this means every vendor running a deep discount is cutting corners. Some genuinely have better supplier costs and are passing it through, which we are always trying to find and pass on to our customers. That’s the honest version of price competition, and it’s real. The problem is you can’t tell the difference from the discount percentage alone. A 60% off badge tells you nothing about purity. It tells you the marketing team is good at their job.

    So what should you actually check, instead of chasing the number?

    • Is the COA batch-specific, or generic? A Certificate of Analysis tied to the exact lot number on your product is worth infinitely more than a “representative” COA posted once and reused across restocks.
    • Can you verify the signature independently? A cryptographically signed COA (verifiable through the testing lab’s own portal, not just trust-the-PDF) means the document can’t be quietly edited after the fact. Most suppliers don’t offer this because most testing labs don’t offer it standard. It costs more.
    • What method did the testing actually use? UV-Vis identity testing is common and it’s honest as far as it goes, but it can’t distinguish some closely related compounds from each other. HPLC and LC-MS can. If a vendor doesn’t say which method was used, that’s the question to ask before you ask about price.
    • Does the discount depend on you never checking again? The vendors worth trusting are the ones who’d still pass this test at full price. If the pitch only works because you’re excited about the percentage, the pitch is doing the work the product should be doing.

    We built Peptide Briefs on the opposite bet: that researchers would rather know exactly where the evidence stands, including the compounds we grade a C, including the batches that failed identity testing and got discarded rather than shipped, than be sold on a discount that changes weekly. That’s also why every Agape Compounds batch carries a signed, independently verifiable COA rather than a static PDF. We’d rather be the supplier you checked and trusted than the one you almost forgot to check because the price looked good.

    The next time a sitewide discount crosses 50%, don’t ask “how do I stack this.” Ask what it would honestly cost to run this business, then ask why this price doesn’t reflect that.

    — Troy

    Peptide Briefs is an independent research library. We test, grade, and document. We don’t chase the discount war.

  • Behind the Science: How We Verify Every Batch

    “Trust us” isn’t a testing methodology. So here’s exactly what happens before any compound reaches you — not a summary, the actual panel.

    The testing panel

    Every batch goes through independent third-party testing at Purity Analytics, a Georgia-based lab, covering:

    • HPLC (High-Performance Liquid Chromatography) — measures purity, confirming what percentage of the vial is actually the compound it claims to be
    • Mass spectrometry — confirms molecular identity, verifying the compound is what it says it is, not just how pure it is
    • Heavy metals (ICP-MS) — screens for contamination from the manufacturing process
    • TAMC/TYMC — total aerobic microbial count and total yeast/mold count, catching biological contamination
    • Endotoxin testing (LAL) — screens for bacterial endotoxins, especially critical for injectable research compounds

    Why the signature matters more than the number

    A COA is only as trustworthy as its origin. Ours are cryptographically signed using PKCS#7/Sectigo digital signatures — the same underlying technology banks use to verify document authenticity. That means the document itself can prove it hasn’t been altered since the lab issued it, and you can verify that signature yourself in Adobe Acrobat, not just take our description of it on faith.

    Every COA is also independently checkable at verify.purityanalytics.com — you don’t need to trust our website’s claim that testing happened; you can go straight to the lab’s own verification system.

    The honest part

    This process isn’t unique to us, it’s what any legitimate research supplier should be doing. What we think is actually worth pointing out: it’s rare to see suppliers publish the full panel rather than a vague “tested for purity” claim. See our [Research Index] for the published literature these compounds are studied against, and check any batch’s COA yourself before you use it.

    This content is provided for research and informational purposes only. Agape Compounds products are not intended for human or animal consumption.